Orange Investment Advisors Inc. Sells 483 Shares of Eli Lilly and Company $LLY

Orange Investment Advisors Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,985 shares of the company’s stock after selling 483 shares during the period. Eli Lilly and Company accounts for approximately 6.0% of Orange Investment Advisors Inc.’s holdings, making the stock its largest holding. Orange Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $47,423,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Beacon Capital Management LLC grew its stake in shares of Eli Lilly and Company by 3.0% during the third quarter. Beacon Capital Management LLC now owns 1,851 shares of the company’s stock valued at $2,142,000 after purchasing an additional 54 shares during the last quarter. Winter & Associates Inc. raised its position in Eli Lilly and Company by 4.7% in the 3rd quarter. Winter & Associates Inc. now owns 377 shares of the company’s stock worth $483,000 after purchasing an additional 17 shares during the last quarter. Compass Ion Advisors LLC raised its position in Eli Lilly and Company by 9.3% in the 3rd quarter. Compass Ion Advisors LLC now owns 2,328 shares of the company’s stock worth $2,694,000 after purchasing an additional 198 shares during the last quarter. Yardley Wealth Management LLC bought a new position in Eli Lilly and Company in the 3rd quarter worth approximately $1,040,000. Finally, Wolff Financial Management LLC lifted its holdings in Eli Lilly and Company by 0.8% during the 3rd quarter. Wolff Financial Management LLC now owns 7,834 shares of the company’s stock worth $9,065,000 after buying an additional 62 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Bank of America boosted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday. Truist Financial upped their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,320.25.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A federal judge rejected Novo Nordisk’s request to block Lilly’s advertisements for its obesity treatments, finding insufficient evidence that the campaign caused meaningful or lasting harm to Novo’s sales. The decision allows Lilly to continue promoting its weight-loss portfolio, including Zepbound. Reuters article
• Positive Sentiment: New early-stage oncology data added to Lilly’s pipeline narrative. Olomorasib reportedly produced a 62% response rate in lung-cancer data, while Phase 1 results for sofe-M plus bevacizumab showed encouraging response and disease-control rates in ovarian cancer without major new safety signals. These results remain preliminary but could support longer-term growth expectations. Lung cancer results
• Positive Sentiment: Bernstein raised its price target for LLY to $1,450 from $1,385, reflecting continued confidence in Mounjaro, Zepbound and Lilly’s broader growth prospects. Commentary also notes that Lilly has significantly outperformed broader equities over the past five years. Bernstein price-target update
• Positive Sentiment: LillyDirect is working with Counsel Health on an AI-enabled, physician-led weight-management program, potentially expanding access and patient engagement around Lilly’s GLP-1 medicines. Counsel Health partnership
• Neutral Sentiment: International business chief Patrik Jonsson will retire at year-end after 36 years, with Ilya Yuffa becoming president of Lilly Global Markets on January 1, 2027. The planned transition is intended to support global expansion, but it introduces a leadership change investors will monitor. Lilly leadership announcement
• Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The 0.5% yield is modest, making the announcement more of a continuity signal than a major valuation catalyst. Dividend announcement
• Negative Sentiment: Ahead of earnings, analysts continue to flag pricing pressure, rising costs and intense competition from Novo Nordisk. Investors will focus on Mounjaro and Zepbound demand, patient growth, revenue realization and updated guidance; strong expectations increase the risk of a muted reaction if results or outlook fall short. Q3 earnings preview

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,283.52 on Wednesday. The company’s 50 day simple moving average is $1,191.27 and its 200 day simple moving average is $1,088.34. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the business posted $6.31 earnings per share. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 33.22 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.